Deutsche Bank AG Grows Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Deutsche Bank AG raised its position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 207.9% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 121,501 shares of the biopharmaceutical company's stock after purchasing an additional 82,042 shares during the quarter. Deutsche Bank AG owned approximately 0.18% of Celldex Therapeutics worth $3,070,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the company. Deep Track Capital LP acquired a new stake in Celldex Therapeutics during the 4th quarter valued at approximately $38,919,000. Crestline Management LP increased its position in Celldex Therapeutics by 114.0% during the 4th quarter. Crestline Management LP now owns 295,354 shares of the biopharmaceutical company's stock valued at $7,464,000 after purchasing an additional 157,366 shares during the period. Cubist Systematic Strategies LLC acquired a new stake in Celldex Therapeutics during the 4th quarter valued at approximately $3,905,000. BNP Paribas Financial Markets boosted its holdings in shares of Celldex Therapeutics by 122.2% during the 4th quarter. BNP Paribas Financial Markets now owns 62,631 shares of the biopharmaceutical company's stock worth $1,583,000 after buying an additional 34,450 shares in the last quarter. Finally, Ameriprise Financial Inc. bought a new position in shares of Celldex Therapeutics during the 4th quarter worth approximately $251,000.

Celldex Therapeutics Trading Down 0.1%

Shares of CLDX traded down $0.02 during trading hours on Friday, reaching $20.35. The stock had a trading volume of 477,438 shares, compared to its average volume of 895,300. Celldex Therapeutics, Inc. has a 12 month low of $14.40 and a 12 month high of $47.00. The firm has a 50-day simple moving average of $18.91 and a 200 day simple moving average of $22.42. The company has a market capitalization of $1.35 billion, a price-to-earnings ratio of -7.92 and a beta of 1.39.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last issued its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.06). Celldex Therapeutics had a negative return on equity of 19.75% and a negative net margin of 1,544.32%. The firm had revenue of $0.70 million during the quarter, compared to the consensus estimate of $1.08 million. On average, equities analysts forecast that Celldex Therapeutics, Inc. will post -2.48 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. Cantor Fitzgerald restated an "overweight" rating and set a $67.00 price target on shares of Celldex Therapeutics in a report on Wednesday, January 29th. Canaccord Genuity Group assumed coverage on Celldex Therapeutics in a report on Monday, April 28th. They set a "buy" rating and a $64.00 price target on the stock. The Goldman Sachs Group cut their price target on Celldex Therapeutics from $36.00 to $31.00 and set a "neutral" rating on the stock in a report on Friday, May 9th. Morgan Stanley cut their price target on Celldex Therapeutics from $46.00 to $43.00 and set an "overweight" rating on the stock in a report on Friday, May 9th. Finally, UBS Group cut their price target on Celldex Therapeutics from $44.00 to $38.00 and set a "buy" rating on the stock in a report on Friday, May 9th. Two investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, Celldex Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $53.90.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.